A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.
EP. 1: Frontline Treatment of Advanced Renal Cell CarcinomaMarch 30th 2021
The panelists discuss frontline treatment for renal cell carcinoma, highlighting TKIs targeting VEGFR and the mechanisms of action for currently approved therapeutics.
EP. 2: Prevalence of Actionable Biomarkers in Clear-Cell RCCApril 20th 2021
Thomas Hutson, DO, PharmD, and Toni Choueiri, MD, discuss the available biomarkers, predictive biomarkers, and clinical predictors that are currently used in metastatic clear-cell renal cell carcinoma, as well as risk status.
EP. 4: FDA-Approved TKI/IO Combinations in mRCCApril 20th 2021
Hutson and Choueiri elaborate on the FDA-approved TKI + ICI combinations and their data from the following trials: KEYNOTE-146, JAVELIN Renal 101, and CheckMate-9ER.
EP. 5: CLEAR Trial: Len + Pembro or Everolimus vs SunitinibApril 20th 2021
Thomas Hutson, DO, PharmD, and Toni Choueiri, MD, talk about the phase 3 CLEAR trial at length, including each of the 3 arms of the trial and key data.
EP. 6: Safety Profile of Len + Pembro From CLEAR in mRCCApril 20th 2021
Hutson and Choueiri compare the safety profiles of lenvatinib + pembrolizumab against other TKI/IO combinations for patients with metastatic clear-cell renal cell carcinoma.
EP. 7: Dosing Strategies for Maximum Efficacy With Len + PembroApril 29th 2021
Dosing strategies to achieve strong efficacy and ameliorate adverse events with the combination of lenvatinib + pembrolizumab in metastatic clear-cell renal cell carcinoma.